Arch Capital Group Interest Paid decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Over 4 years (FY 2021 to FY 2025), Interest Paid shows relatively stable performance with a -2.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $34.75M | $34.75M | $34.75M | $32.00M | $32.00M | $32.00M | $32.00M | $0.00 | $63.00M | $0.00 | $64.00M | $0.00 | $63.00M | $0.00 | $64.00M | $0.00 | $64.00M | $0.00 | $63.00M | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | -7.9% | +0.0% | +0.0% | +0.0% | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% |
| YoY Change | — | — | — | — | -7.9% | -7.9% | -7.9% | -100.0% | +96.9% | -100.0% | +100.0% | — | +0.0% | — | +0.0% | — | +1.6% | — | -1.6% | — |